Investor's Business Daily on MSN18m
Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug FailsBristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback